Evidence tracker Pharmacology Delirium prevention

Dexmedetomidine to prevent postoperative delirium

Does perioperative dexmedetomidine prevent delirium, and in whom? Compare dosing and timing, cardiac versus noncardiac surgery, and delirium outcomes alongside bradycardia and hypotension.

Indexed papers
19
matching, retractions excluded
Randomized trials
4
plus 2 meta-analyses
With AI summary
19
others show original abstract
Registered, not results
0
ongoing trials
Clinical assessment not completed. No bottom line, certainty grade, or curated effect sizes have been written for this topic. Below is a source-linked inventory of matching papers (up to 200 from our cache), not a systematic review. Read the original studies before drawing conclusions.

Published studies

Open in feed

Recent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.

Showing 2 of 19 · Meta-analysis

Recent evidence · past year

  1. Meta-analysis Front NeurolPublished 12 Aug 2026 Li A et al.
    Efficacy and hemodynamic safety of perioperative dexmedetomidine for the prevention of postoperative delirium in elderly patients undergoing cardiac surgery: an updated systematic review and meta-analysis of randomized controlled trials.
    AI summary of the abstract, unverified
    • Systematic review and meta-analysis of 15 RCTs including 3,274 older adults undergoing cardiac surgery.
    • Perioperative dexmedetomidine was compared with placebo or alternative sedative or analgesic regimens for preventing postoperative delirium.
    • Dexmedetomidine lowered postoperative delirium incidence (RR 0.70, 95% CI 0.56 to 0.86, p = 0.001; moderate certainty) but increased reported bradycardia (RR 2.08, 95% CI 1.31 to 3.31).
    • The benefit appeared larger against active comparators than placebo or saline. The delirium duration reduction (MD -1.12 days) was low certainty with high heterogeneity.
    Original abstract (PubMed)

    BACKGROUND: Postoperative delirium (POD) is a common and clinically important complication after cardiac surgery in older adults. We performed an updated systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy and hemodynamic safety of perioperative dexmedetomidine for POD prevention in older adults undergoing cardiac surgery. METHODS: We searched PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials from inception through July 12th, 2026 for RCTs comparing perioperative dexmedetomidine with placebo or alternative sedative /analgesic regimens in elderly patients aged 60 years or older, or in extractable elderly subgroups, undergoing cardiac surgery. Primary outcomes were POD incidence and delirium duration. Secondary outcomes included length of intensive care unit (ICU) stay, length of hospital stay, and the risk of bradycardia and hypotension. RESULTS: Fifteen RCTs involving 3,274 patients were included. Perioperative dexmedetomidine was associated with a lower incidence of POD (Risk Ratio [RR] 0.70, 95% Confidence Interval [CI] 0.56 to 0.86, p = 0.001, I2 = 19%; GRADE: moderate certainty) and shorter duration of delirium among patients with POD (Mean Difference [MD] -1.12 days, 95% CI -1.89 to -0.35, p = 0.01, I2 = 83%; GRADE: low certainty). The apparent benefit was more evident in active-comparator trials than in placebo/saline-controlled trials, but this comparator-dependent pattern should not be interpreted as proof of a uniform neuroprotective effect. However, dexmedetomidine was associated with increased bradycardia (RR 2.08, 95% CI 1.31 to3.31, p = 0.0019, I2 = 0%; GRADE: low certainty). No significant differences were observed for length of ICU stay, length of hospital stay, or hypotension. CONCLUSION: Perioperative dexmedetomidine may reduce POD incidence in selected older cardiac surgery patients, particularly when compared with selected active sedative or analgesic regimens. However, the certainty of evidence was moderate, and the effect was less clear in saline/placebo-controlled trials. Evidence for delirium duration was based on few affected patients, showed substantial heterogeneity, and should not drive the main clinical conclusion. Dexmedetomidine increased reported bradycardia, and clinical use should be individualized with careful hemodynamic monitoring. SYSTEMATIC REVIEW REGISTRATION: https://osf.io/f6nwu.

  2. Meta-analysis Neurocrit CarePublished 18 May 2026 Dos Reis MAOM et al.
    Efficacy of Dexmedetomidine in Preventing Postoperative Delirium in Patients Undergoing Brain Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    AI summary of the abstract, unverified
    • Systematic review and meta-analysis of five randomized controlled trials, including 646 adults undergoing brain surgery, with searches run through April 2025.
    • Evaluated perioperative dexmedetomidine, given as a loading dose followed by a maintenance infusion, for preventing postoperative delirium.
    • The pooled risk ratio was 0.47 (95% CI 0.35-0.63; p < 0.00001), a 53% reduction in delirium risk, with no heterogeneity (I2 = 0%).
    • Subgroups showed similar effects across brain tumor and other cranial procedures, adverse events were comparable and mostly mild, and the authors call for multicenter trials.
    Original abstract (PubMed)

    BACKGROUND: Dexmedetomidine (DEX), a selective alpha-2 adrenergic receptor agonist, is widely used in various surgical settings, including cardiac and general surgeries, for its sedative, analgesic, and neuroprotective properties. Patients undergoing brain surgery are particularly susceptible to postoperative delirium (POD). Given the established benefits of dexmedetomidine in other surgical fields, its potential to mitigate delirium in neurosurgery warrants investigation. METHODS: A systematic search of PubMed, Embase, Scopus, and Cochrane databases was conducted from inception to January 2025 and updated in April 2025, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Risk of bias was assessed, and a meta-analysis was performed using Review Manager 5.4.1. Five randomized controlled trials were included, evaluating the efficacy of DEX in preventing POD in adult patients undergoing brain surgery. RESULTS: A total of 646 patients were enrolled, with DEX administered with a loading dose ranging from 0.5 to 1 μg/kg over 10 min, followed by a maintenance infusion rate of 0.1 to 0.5 μg/kg/h during the surgical procedure. The pooled risk ratio (RR) for POD with DEX was 0.47 (95% confidence interval (CI): 0.35-0.63; p < 0.00001); reflecting a 53% reduction in the risk of postoperative delirium, with no statistical heterogeneity detected (χ2 = 2.09, degrees of freedom (df) = 4, p = 0.72; I2 = 0%). Subgroup analyses showed similar effect estimates across brain tumor and other cranial procedures. Adverse events were comparable between groups and generally mild. CONCLUSIONS: This meta-analysis found that perioperative dexmedetomidine was associated with a significant reduction in postoperative delirium risk in neurosurgical patients. Further multicenter trials are needed to confirm these findings and to refine optimal administration strategies.

Earlier evidence / dates not confirmed

Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.

  1. No matching papers in this section with the selected filters.

Ongoing registrations

From ClinicalTrials.gov

Registrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.

No registered ongoing trials found.